Clinical Trials
135 trialsCOM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
REALIZE
University of Oklahoma
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Massachusetts General Hospital
CALySSEY
Baylor College of Medicine
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Gilead Sciences
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
K36 Therapeutics, Inc.
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
FT576 in Subjects With Multiple Myeloma
Fate Therapeutics
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
H. Lee Moffitt Cancer Center and Research Institute
DC15-MM-01
Cartesian Therapeutics
Stem Cell Transplantation for Patients With Multiple Myeloma
University of Chicago
CHARKALL
Baylor College of Medicine
Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
Washington University School of Medicine
High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
University of Arkansas
Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation
Hospital Universitario Dr. Jose E. Gonzalez
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Seagen Inc.
Descartes-25 in Relapsed/Refractory Multiple Myeloma
Cartesian Therapeutics
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Servier
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
Taiho Oncology, Inc.
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
OriCell Therapeutics Co., Ltd.
A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene
Myelofludate
Nantes University Hospital
FT538 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
Eastern Cooperative Oncology Group
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Celularity Incorporated
A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
Genentech, Inc.
Phase 1 Trial of CXD101 in Patients With Advanced Cancer
Oxford University Hospitals NHS Trust
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
Novartis
Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
Novartis
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
Novartis
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Novartis
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
OHSU Knight Cancer Institute
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Case Comprehensive Cancer Center
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
Celularity Incorporated
Vaccination With PD-L1 Peptide Against Multiple Myeloma
Herlev Hospital
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Ohio State University Comprehensive Cancer Center
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Celgene
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Abramson Cancer Center at Penn Medicine
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison
Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
ToTem
University College, London
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
University of Maryland, Baltimore
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic